<p>Pharming Group N.V. 赞助的 ADR (NASDAQ:PHAR - 获取免费报告) 的股票在周四创下了新的 52 周高点。该公司的交易最高达到 $19.46，最后交易价格为 $19.50，成交量为 3758 股。该股票之前的收盘价为 $17.92。</p>
<p>获取 <strong>Pharming Group</strong> 的提醒：</p>
<h2>华尔街分析师观点</h2>
<p>几位股票研究分析师最近对 PHAR 股票发表了评论。Wall Street Zen 在 12 月 27 日的研究报告中将 Pharming Group 的评级上调至 &#34;强力买入&#34;。Weiss Ratings 在 12 月 22 日的报告中重申了对 Pharming Group 股票的 &#34;持有 (c-)&#34; 评级。最后，Zacks Research 在 1 月 1 日的研究报告中将 Pharming Group 的股票评级从 &#34;强力买入&#34; 下调至 &#34;持有&#34;。两位股票研究分析师给予该股票买入评级，两位给予公司持有评级。根据 MarketBeat 的数据，该公司的共识评级为 &#34;适度买入&#34;，共识目标价为 $38.00。</p>
<p><strong>查看我们对 Pharming Group 的最新分析</strong></p>
<h2>Pharming Group 价格表现</h2>
<p>该公司的速动比率为 2.39，流动比率为 3.16，债务与股本比率为 0.35。该公司的市值为 13.9 亿美元，市盈率为 -1,970.03。公司的 50 日移动平均线为 $17.26，200 日移动平均线为 $14.60。</p>
<p>Pharming Group (NASDAQ:PHAR - 获取免费报告) 最近在 11 月 6 日宣布了其季度财报。该公司报告每股收益 (EPS) 为 $0.10，超出市场共识预期的 $0.05，超出幅度为 $0.05。该公司在本季度的收入为 9730 万美元，而分析师预期为 9822 万美元。Pharming Group 的净利润率为 0.30%，股本回报率为 0.46%。股票研究分析师预计 Pharming Group N.V. 赞助的 ADR 在当前财政年度将发布 -0.2 的每股收益。</p>
<h2>Pharming Group 的机构交易</h2>
<p>一家对冲基金最近在 Pharming Group 股票中购买了新股份。EverSource Wealth Advisors LLC 在第二季度购买了 Pharming Group N.V. 赞助的 ADR (NASDAQ:PHAR - 免费报告) 的新股份，根据其最近向证券交易委员会的备案。该基金购买了 2979 股该公司的股票，价值约为 $32,000。机构投资者持有该公司 0.03% 的股票。</p>
<h2>关于 Pharming Group</h2>
<p>(获取免费报告)</p>
<p>Pharming Group N.V. 是一家临床阶段的生物制药公司，总部位于荷兰莱顿，主要专注于开发和商业化创新的蛋白质替代疗法，以帮助罹患罕见疾病的患者。该公司采用专有的转基因技术平台，旨在在转基因动物的乳汁中生产重组人类蛋白质，从而实现复杂治疗蛋白质的可扩展和成本有效的生产。</p>
<p>该公司的主要产品 RUCONEST（重组人类 C1 酯酶抑制剂）已在多个市场获得批准，用于治疗急性遗传性血管性水肿 (HAE) 发作，包括美国和欧洲。</p>
<h2>推荐故事</h2>
<ul>
<li>我们更看好的五只股票，而不是 Pharming Group</li>
<li>政府印刷了数万亿，白银供应有限。</li>
<li>您的签名缺失 - 请在为时已晚之前采取行动</li>
<li>华尔街警报：购买 AES</li>
<li>特朗普做了什么？？</li>
<li>1933 年的退款：特朗普的重置可能创造即时财富</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>您现在应该投资 $1,000 在 Pharming Group 吗？</h2>
<p>在您考虑 Pharming Group 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买... 而 Pharming Group 并不在名单上。</p>
<p>虽然 Pharming Group 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

基因改革 ETF - ARK

生物科技 ETF - VanEck Vectors

医疗业 ETF - SPDR

<p>Pharming Group（纳斯达克代码：PHAR）达到了新的 52 周高点 19.50 美元，较之前的收盘价 17.92 美元上涨。分析师的评级意见不一，其中两位推荐买入，另外两位维持持有，导致共识评级为 “适度买入”，目标价为 38.00 美元。该公司报告每股收益为 0.10 美元，超出预期，收入为 9730 万美元。机构持股比例较低，仅为 0.03%。Pharming 专注于罕见疾病的创新疗法，其主打产品 RUCONEST 已在多个市场获得批准</p>

<p>Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Get Free Report) shares hit a new 52-week high on Thursday . The company traded as high as $19.46 and last traded at $19.50, with a volume of 3758 shares changing hands. The stock had previously closed at $17.92.</p>
<div class="lb-trans"><p>Pharming Group N.V. 赞助的 ADR (NASDAQ:PHAR - 获取免费报告) 的股票在周四创下了新的 52 周高点。该公司的交易最高达到 $19.46，最后交易价格为 $19.50，成交量为 3758 股。该股票之前的收盘价为 $17.92。</p>
</div><p>Get <strong>Pharming Group</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Pharming Group</strong> 的提醒：</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>Several equities research analysts recently commented on PHAR shares. Wall Street Zen raised Pharming Group to a &#34;strong-buy&#34; rating in a research note on Saturday, December 27th. Weiss Ratings restated a &#34;hold (c-)&#34; rating on shares of Pharming Group in a report on Monday, December 22nd. Finally, Zacks Research cut shares of Pharming Group from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research note on Thursday, January 1st. Two equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $38.00.</p>
<div class="lb-trans"><p>几位股票研究分析师最近对 PHAR 股票发表了评论。Wall Street Zen 在 12 月 27 日的研究报告中将 Pharming Group 的评级上调至 &#34;强力买入&#34;。Weiss Ratings 在 12 月 22 日的报告中重申了对 Pharming Group 股票的 &#34;持有 (c-)&#34; 评级。最后，Zacks Research 在 1 月 1 日的研究报告中将 Pharming Group 的股票评级从 &#34;强力买入&#34; 下调至 &#34;持有&#34;。两位股票研究分析师给予该股票买入评级，两位给予公司持有评级。根据 MarketBeat 的数据，该公司的共识评级为 &#34;适度买入&#34;，共识目标价为 $38.00。</p>
</div><p><strong>Check Out Our Latest Analysis on Pharming Group</strong></p>
<div class="lb-trans"><p><strong>查看我们对 Pharming Group 的最新分析</strong></p>
</div><h2>Pharming Group Price Performance</h2>
<div class="lb-trans"><h2>Pharming Group 价格表现</h2>
</div><p>The company has a quick ratio of 2.39, a current ratio of 3.16 and a debt-to-equity ratio of 0.35. The firm has a market capitalization of $1.39 billion and a price-to-earnings ratio of -1,970.03. The company's fifty day moving average is $17.26 and its two-hundred day moving average is $14.60.</p>
<div class="lb-trans"><p>该公司的速动比率为 2.39，流动比率为 3.16，债务与股本比率为 0.35。该公司的市值为 13.9 亿美元，市盈率为 -1,970.03。公司的 50 日移动平均线为 $17.26，200 日移动平均线为 $14.60。</p>
</div><p>Pharming Group (NASDAQ:PHAR - Get Free Report) last announced its quarterly earnings results on Thursday, November 6th. The company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.05 by $0.05. The company had revenue of $97.30 million during the quarter, compared to analyst estimates of $98.22 million. Pharming Group had a net margin of 0.30% and a return on equity of 0.46%. Equities research analysts anticipate that Pharming Group N.V. Sponsored ADR will post -0.2 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Pharming Group (NASDAQ:PHAR - 获取免费报告) 最近在 11 月 6 日宣布了其季度财报。该公司报告每股收益 (EPS) 为 $0.10，超出市场共识预期的 $0.05，超出幅度为 $0.05。该公司在本季度的收入为 9730 万美元，而分析师预期为 9822 万美元。Pharming Group 的净利润率为 0.30%，股本回报率为 0.46%。股票研究分析师预计 Pharming Group N.V. 赞助的 ADR 在当前财政年度将发布 -0.2 的每股收益。</p>
</div><h2>Institutional Trading of Pharming Group</h2>
<div class="lb-trans"><h2>Pharming Group 的机构交易</h2>
</div><p>A hedge fund recently bought a new stake in Pharming Group stock. EverSource Wealth Advisors LLC purchased a new stake in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 2,979 shares of the company's stock, valued at approximately $32,000. Institutional investors own 0.03% of the company's stock.</p>
<div class="lb-trans"><p>一家对冲基金最近在 Pharming Group 股票中购买了新股份。EverSource Wealth Advisors LLC 在第二季度购买了 Pharming Group N.V. 赞助的 ADR (NASDAQ:PHAR - 免费报告) 的新股份，根据其最近向证券交易委员会的备案。该基金购买了 2979 股该公司的股票，价值约为 $32,000。机构投资者持有该公司 0.03% 的股票。</p>
</div><h2>About Pharming Group</h2>
<div class="lb-trans"><h2>关于 Pharming Group</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.</p>
<div class="lb-trans"><p>Pharming Group N.V. 是一家临床阶段的生物制药公司，总部位于荷兰莱顿，主要专注于开发和商业化创新的蛋白质替代疗法，以帮助罹患罕见疾病的患者。该公司采用专有的转基因技术平台，旨在在转基因动物的乳汁中生产重组人类蛋白质，从而实现复杂治疗蛋白质的可扩展和成本有效的生产。</p>
</div><p>The company's lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.</p>
<div class="lb-trans"><p>该公司的主要产品 RUCONEST（重组人类 C1 酯酶抑制剂）已在多个市场获得批准，用于治疗急性遗传性血管性水肿 (HAE) 发作，包括美国和欧洲。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Pharming Group</li>
<li>The Government Prints Trillions. Silver Supply Is Limited.</li>
<li>Your Signature Is Missing – Act Before It’s Too Late</li>
<li>Wall Street Alert: Buy AES</li>
<li>Trump Did WHAT??</li>
<li>Refund From 1933: Trump’s Reset May Create Instant Wealth</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Pharming Group</li>
<li>政府印刷了数万亿，白银供应有限。</li>
<li>您的签名缺失 - 请在为时已晚之前采取行动</li>
<li>华尔街警报：购买 AES</li>
<li>特朗普做了什么？？</li>
<li>1933 年的退款：特朗普的重置可能创造即时财富</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Pharming Group Right Now?</h2>
<div class="lb-trans"><h2>您现在应该投资 $1,000 在 Pharming Group 吗？</h2>
</div><p>Before you consider Pharming Group, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考虑 Pharming Group 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买... 而 Pharming Group 并不在名单上。</p>
</div><p>While Pharming Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Pharming Group 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Pharming Group (NASDAQ:PHAR) Sets New 12-Month High  - What's Next?

Market Beat

医药突破 ETF - ALPS

Pharming Group NV

2 倍做多纳斯达克生物技术 ETF - ProShares

动态生物技术与基因组 ETF - Invesco

美国制药 ETF - iShares

Invesco Nasdaq Biotechnology ETF

医疗业 ETF - Vanguard

标普生物技术 ETF - SPDR

纳斯达克生物科技指数 ETF - iShares Nasdaq

纽交所高增长板生物技术指数 ETF - First Trust

Pharming Group（NASDAQ:PHAR）创下新的 12 个月高点 - 接下来会发生什么？